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http://dx.doi.org/10.1016/j.ccell.2016.08.005SUMMARYMetabolic adaptability is essential for tumor progression and includes cooperation between cancer cells with
different metabolic phenotypes. Optimal glucose supply to glycolytic cancer cells occurs when oxidative
cancer cells use lactate preferentially to glucose. However, using lactate instead of glucose mimics glucose
deprivation, and glucose starvation induces autophagy. We report that lactate sustains autophagy in cancer.
In cancer cells preferentially to normal cells, lactate dehydrogenase B (LDHB), catalyzing the conversion of
lactate and NAD+ to pyruvate, NADH and H+, controls lysosomal acidification, vesicle maturation, and intra-
cellular proteolysis. LDHB activity is necessary for basal autophagy and cancer cell proliferation not only in
oxidative cancer cells but also in glycolytic cancer cells.INTRODUCTION
Cancer can be viewed as a metabolic disease in which cancer
cells strive to fulfill their proliferative agenda in a microenviron-
ment characterized by uneven and fluctuating resource bioavail-
ability. Oxygen and nutrient shortage are well-known character-
istics of cancer that result from a mismatch between supply and
use, inherent to blood perfusion abnormalities and high con-
sumption rates (Walenta et al., 2001; Dewhirst et al., 2008). At
least three different evolutionary metabolic strategies allow can-
cer cells to cope with fluctuating resource availability.
First, unlike most normal cells, cancer cells are characterized
by a high metabolic plasticity allowing them to switch substrates
depending on availability. While hypoxic cancer cells are
addicted to glucose-fueled anaerobic glycolysis, oxidative can-
cer cells close to tumor-feeding blood vessels can use severalSignificance
Autophagy promotes cancer cell survival and proliferation by r
tive stress and by ensuringmetabolite supplementation under
B (LDHB) controls autophagy in cancer. LDHB catalyzes the con
reaction promotes lysosomal acidification dependent on V-ATP
essential for vesicle maturation and protease activation during
motes autophagy in oxidative and glycolytic cancer cells. Con
proliferation of cancer cells preferentially to normal differentia
418 Cancer Cell 30, 418–431, September 12, 2016 ª 2016 Elsevier Inprecursor substrates in order to fuel oxidative phosphorylation,
among which glucose, glutamine, lactate, and lipids represent
the main available pools (Porporato et al., 2011; Dhup et al.,
2012; Hensley et al., 2013). Fine-tuning the biosynthetic/bioener-
getic balance is controlled at the enzymatic level to match cell
needs (Warburg, 1956; Mazurek, 2011; Mullen et al., 2012).
Upon nutrient starvation, a metabolic strategy of cancer cells
is to increase autophagy (White, 2012). During the autophagic
process, an autophagosome is formed that isolates targeted or
non-specific material. This content then undergoes enzymatic
degradation after fusion of the autophagosome with lysosomes
that provide protons and acid-activated proteases to the so-
formed autolysosome (Levine and Kroemer, 2008). Degradation
products can then be exported or recycled (Rabinowitz and
White, 2010). Either excessive or long-term activation of auto-
phagy or its inhibition with agents such as chloroquine mayecycling damaged proteins and organelles in case of oxida-
nutrient starvation. We identified that lactate dehydrogenase
version of lactate andNAD+ to pyruvate, NADH, andH+. This
ase, a proton pumpof lysosomes. Lysosomal acidification is
autophagy. Consequently, lactate oxidation by LDHB pro-
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lead to cell death (Maclean et al., 2008; Yoon et al., 2010).
Inhibition of autophagy in particular constitutes a promising ther-
apeutic approach against cancer. Autophagy also offers cyto-
protection by recycling damaged proteins and organelles when
cancer cells face redox stress (White, 2012). Additional meta-
bolic resources can be obtained when cancer cells exploit the
metabolic activities of stromal cells, such as fibroblasts, adipo-
cytes, and muscle cells (Commisso et al., 2013; Icard et al.,
2014), an extreme form of which is cannibalism for nutrient and
functional organelle supply (Krajcovic and Overholtzer, 2012;
Tan et al., 2015).
A third metabolic strategy promoting tumor progression is
cooperativeness. A good example is when oxidative cancer cells
oxidatively recycle lactate provided by glycolytic cancer cells,
thus sparing glucose and optimizing its bioavailability as a glyco-
lytic fuel for hypoxic cancer cells (Sonveaux et al., 2008; Ken-
nedy et al., 2013). The oxidative use of lactate by oxygenated
cancer cells depends on its uptake, a process facilitated by
monocarboxylate transporters (MCTs, of which MCT1 is the
main contributor), and on the oxidation of lactate in pyruvate
by lactate dehydrogenase B (LDHB). Pyruvate then fuels the
tricarboxylic acid cycle (Dhup et al., 2012). This pathway re-
presses glycolysis because of a competition between LDHB
and the glycolytic enzyme glyceraldehyde-3-phosphate dehy-
drogenase for NAD+ and owing to an allosteric inhibition of
glycolytic enzymes hexokinase and phosphofructokinase-1 by
lactate (Leite et al., 2011; Dhup et al., 2012). Cooperativeness
based on the preferential use of lactate compared with glucose
by oxidative cancer cells was coined metabolic symbiosis (Son-
veaux et al., 2008). It is a hallmark of many cancer types (Son-
veaux et al., 2008; Ho et al., 2012; Guillaumond et al., 2013; Curry
et al., 2013; Kennedy et al., 2013). However, while improved
glucose delivery is a net advantage for glycolytic cancer cells,
its benefit for oxidative cancer cells is still elusive. This study ad-
dresses this open question.
RESULTS
LDHB Controls Tumor Progression and Cancer Cell
Proliferation
Using oxidative SiHa human cervix adenocarcinoma cells as
main model, we previously proposed that oxidative lactate
metabolism is at the core of a metabolic symbiosis based onFigure 1. Silencing LDHB Delays Tumor Growth and Decreases Cance
(A) SurvExpress gene expression database analysis of potential markers of overa
per group).
(B) Tumor growth of SiHa cancer cells carrying a TET-on control shRNA (shCTR) o
(1 mg/mL) or vehicle via the drinking water starting 1 day after cell inoculation (n
(C and D) LDHB and LDHA protein expression (C) and cleaved caspase-3 (D
experiment (n = 8).
(E) Immunohistochemical detection and quantification of proliferation marker Ki-
shown in (B) (scale bar represents 1 mm in the top panels and 200 mm in the bot
(F) Representative western blots of SiHa cells harboring shCTR or shLDHB-1 trea
number after 3 and 10 days of treatment (n = 4). Results at day 10 involved repla
(G) Cancer cells were transfected with a control siRNA (siCTR) or with siRNAs ag
(H) As in (G) but using nonmalignant cells (n = 4–6).
All data represent means ± SEM. *p < 0.05, **p < 0.001, ***p < 0.005; ns, not sign
Wilcoxon matched-pairs signed rank test (D), one-way ANOVA and Holm-Sidak’s
See also Figure S1.
420 Cancer Cell 30, 418–431, September 12, 2016the exchange of lactate in cancer (Sonveaux et al., 2008; Dhup
et al., 2012). This pathway requires MCT1-facilitated lactate up-
take and lactate oxidation to pyruvate by LDHB (Halestrap and
Wilson, 2012). To further demonstrate the significance of lactate
oxidation in cancer, we retrospectively analyzed a microarray
dataset of 332 uterine cancer patients. We found that high
expression of MCT1/SLC16A1 together with LDHB predicts
poor overall patient survival (Figure 1A). Taken independently,
MCT1 and LDHB were significantly associated with poor patient
prognosis, but LDHA, catalyzing the reduction of pyruvate to
lactate in glycolytic cancer cells, was not. Clinical data thus sug-
gested that, contrary to its closest relative LDHA, LDHB could
control the clinical progression of uterine cancers. We therefore
aimed to experimentally characterize the specific contribution of
LDHB to tumor progression. We engineered SiHa cells express-
ing a TET-on small hairpin RNA (shRNA) targeting LDHB
(shLDHB-1) or a control shRNA (shCTR), which were used to
generate tumors in mice. To preserve tumor take, doxycycline
was administered 1 day after tumor implantation. Compared
with shCTR, doxycycline-induced shLDHB-1 expression caused
significant yet transient tumor growth retardation (Figure 1B).
Analysis of tumors at the end of the experiments revealed no
re-expression of LDHB and no compensation of LDHB silencing
by increased LDHA expression (Figure 1C). Silencing LDHB was
associated with increased apoptosis (caspase-3 cleavage, Fig-
ure 1D) and decreased cell proliferation (Figure 1E). In vitro as-
says using the same system (cells were treated for 7 days with
doxycycline, then an equal number of cells were plated for an
additional 3 days of treatment with doxycycline) recapitulated
our in vivo observations by showing an early but not a late
decrease in SiHa cell number by shLDHB-1, despite effective
LDHB silencing (Figure 1F). We used the same strategy to induce
a second inducible shRNA (shLDHB-2) in mice bearing an
HCT116 human colon carcinoma xenograft. Doxycycline was
administered 12 days after tumor implantation once tumors
reached 5 mm in diameter. Silencing LDHB caused significant
HCT116 growth retardation (Figures S1A and S1B).
Our data indicated that, in cancers, LDHB controls early tumor
progression and the number of cancer cells, and negatively af-
fects patient survival. To better delineate the contribution of
LDHB to malignancy, we tested other cancer cell lines. Silencing
LDHBwith a small interfering RNA (siRNA) (siLDHB-2) decreased
cell number in all the cancer cell lines that we investigated: HeLar Cell Number
ll survival in uterine cancer patients (n = 332 patients in total; 164–168 patients
r a TET-on shRNA targeting LDHB (shLDHB-1) in mice treated with doxycycline
= 8 mice per group).
) in the lysates of tumors collected from animals killed at the end of the
67 in tumors treated with doxycycline collected at the end of the experiment
tom panels; n = 8).
ted with or without doxycycline (0.5 mg/mL) for 3 days and quantification of cell
ting an equal number of cells at day 7, then letting them grow for 3 more days.
ainst LDHB (siLDHB-1 or siLDHB-2) and counted 72 hr later (n = 3–4).
ificant, by log rank test (A), two-way ANOVA (B), Mann-Whitney test (C and E),
multiple comparison test (F), or two-tailed unpaired Student’s t test (G and H).
cervix cancer cells, MCF7 human breast cancer cells, HCT116
and WiDr human colon carcinoma cells, SKOV3 human ovarian
carcinoma cells, and T98G and U373 human glioblastoma cells
(Figures 1G, S1C, and S1D). Comparatively, siLDHB did not
affect the number of normal differentiated BJ human skin fibro-
blasts, HUVECs (human umbilical vein endothelial cells), and
MCF10A human mammary gland epithelial cells (Figures 1H
and S1E). However, the number of fetal HLF-1 fibroblasts was
decreased by siLDHB. These observations justified further mo-
lecular investigation.
Targeting LDHB Selectively Inhibits Basal Autophagic
Flux in Oxidative Cancer Cells
In oxidative cancer cells, the oxidative use of lactate preferen-
tially to glucose could mimic glucose deprivation (Sonveaux
et al., 2008; Leite et al., 2011), and glucose deprivation stimu-
lates autophagy. Because unlike normal cells most cancer cells
have a high level of basal autophagy (White, 2012; Avalos et al.,
2014), we hypothesized that LDHB could control autophagy
in cancer. To test this hypothesis, we first investigated com-
binations of siLDHB with known inhibitors of autophagy: chloro-
quine (Maclean et al., 2008) and an siRNA targeting ULK1
(siULK1), a serine/threonine-protein kinase that activates auto-
phagy by phosphorylating beclin-1 (Russell et al., 2013). Individ-
ually, siLDHB decreased SiHa cell number as efficiently as
chloroquine (Figures 2A, S2A, and S2B) and siULK1 (Figure 2B).
There was no additive effect when combining siLDHB with
chloroquine or with siULK1, indicating that these inhibitors target
the same biological pathway. siLDHB and siULK1 were also
equally potent and had no additive effects when used in combi-
nation in HeLa oxidative cervix cancer cells (Figure S2C). We
further verified in both cell lines that siLDHB did not influence
ULK1 and that siULK1 did not influence LDHB protein expres-
sion (Figure S2D). Similar to chloroquine, siLDHB induced both
pro-apoptotic (Figures 2C and 2D) and antiproliferative (Fig-
ure 2E) effects on SiHa cells.
To demonstrate that LDHB controls autophagy in cancer cells,
we first determined the abundance of LC3-II, a protein recruited
to autophagic vesicles and a marker of the autophagic flux (Ru-
binsztein et al., 2009). Silencing LDHB induced leupeptin-sensi-
tive LC3-II protein accumulation in SiHa cells (Figures 2F and
S2E), which represented a potent inhibition of the autophagic
flux (1.67–0.70) (Figure 2F), and was associated with accumula-
tion of autophagic substrate optineurin (Korac et al., 2013) (Fig-
ure 2G). Similar data were obtained using HeLa cells, where
autophagic LC3-II flux decreased (Figure S2F) and optineurin
degradation was prevented (Figure S2G) by siLDHB.
Next, we tested the selectivity of LDHB versus LDHA in pro-
moting autophagy in cancer cells. Having verified that siLDHB
did not alter LDHA expression in SiHa cells (Figure S2A), we
repeated autophagic flux experiments using a siRNA targeting
LDHA (Figure S2H). siLDHA did not decrease SiHa cell number
(Figure 2H) and did not alter the autophagic flux determined
with LC3-II (Figure 2I) and optineurin (Figure 2J). Similarly,
siLDHB did not alter LDHA expression in HeLa cells (Figure S1C)
and siLDHA had no effect on the autophagic flux of these cells
(Figures S2H–S2J). Together, these data demonstrate that
LDHB but not LDHA controls the basal autophagic flux of oxida-
tive cancer cells.The control of basal autophagy by LDHBwas selective to can-
cer cells, as siLDHB did not repress the growth and autophagic
flux of nonmalignant BJ, HUVEC, and MCF10A cells to the
exception of fetal HFL-1 fibroblasts (Figures S2K and S2L). It
was confirmed using a second siRNA and doxycycline-induced
shLDHB-1 that did not increase the abundance of optineurin
except in fetal HFL-1 fibroblasts (Figures S1E and S2M–S2P).
Chloroquine caused optineurin accumulation only in HFL-1 fibro-
blasts, resulting in cell death (Figures S2N and S2P); it also
reduced the number of MCF10A cells but independently of opti-
neurin accumulation (Figures S2M and S2O).
LDHB Controls Autophagic Vesicle Maturation
We examined vesicle trafficking to understand how LDHB
regulates autophagy. During autophagy, lysosomes fuse with
autophagosomes to form autolysosomes containing active pro-
teases. LDHB was expressed in the lysosomal fraction of SiHa
cells (Figure 3A). Silencing of LDHB caused the accumulation
of vesicles (Figure 3B) that were acidic (Figure 3C) and ex-
pressed the lysosomal marker LAMP-1 (Figure 3D). Acidic
vesicle accumulation was also observed with chloroquine, with
no additive effects of siLDHB on chloroquine (Figure 3C), sug-
gesting that both treatments induce a lysosomal dysfunction
that results in lysosome accumulation. Overexpressing LDHB
had the opposite effect; it decreased the number of acidic vesi-
cles per cell (Figures 3C and S3A). Of note, siLDHB did not affect
the subcellular distribution pattern of lysosomes (distance to cell
nucleus, Figure 3E).
Because there was no additive effect of siLDHB on the genetic
disruption of autophagy by siULK1, which targets an early step of
autophagy (Figure 2B), and no additive effect of siLDHB on auto-
phagy inhibition by chloroquine, which inhibits lysosomal activity
(Figure 2A), we hypothesized that LDHB controls autophagic
vesicle maturation. Accordingly, siLDHB repressed the fusion
between lysosomes and autophagosomes, which was demon-
strated by a decrease in the number of vesicles that coex-
pressed LAMP-1 and LC3 (Figure 3F). Similarly to chloroquine,
siLDHB also decreased the abundance of mature autolyso-
somes measured using a LC3-mRFP-GFP reporter (Kimura
et al., 2007) (Figure 3G). Defective fusion was associated with
the accumulation of lysosomes (Figure 3D) and LC3-positive
autophagosomes (Figure 3H). siLDHB decreased intracellular
proteolysis, which was demonstrated by decreased DQ-BSA
dequenching (Figures 3I and S3B), whereas the early endocytic
pathway was intact (Figure S3C).
Together, these data show that siLDHB induces lysosomal in-
hibition in oxidative cancer cells, thus positioning LDHB as an
important contributor to lysosomal activity. This conclusion is
supported by the fact that LDHB overexpression increased
mature autolysosome formation (Figures 3J and S3D) and intra-
cellular proteolysis (Figures 3K and S3E) in SiHa and in HeLa
cells.
LDHB Actively Controls Lysosomal Activity in Oxidative
Cancer Cells
To test whether LDHB controls the lysosomal function through
its enzymatic activity, we first produced vectors encoding HA-
tagged catalytically inactive halves of the protein (hLDHBD163-








Figure 2. Silencing LDHB Inhibits Autophagy in SiHa Oxidative Cancer Cells
(A) Numbers of cells that were transfected for 72 hr with siCTR or siLDHB-1 and treated with or without 20 mM chloroquine for the last 48 hr (n = 6).
(B) Numbers of cells at 72 hr after transfection with siCTR, siLDHB, siULK1, or siLDHB + siULK1 (n = 5).
(C) Cell death measured by trypan blue exclusion of cells transfected as indicated and then treated with or without 20 mM chloroquine for 48 hr (n = 9–12).
(D) Representative western blot and quantification of cleaved caspase-3 of cells at 72 hr after transfection as indicated (n = 3).
(E) Cell proliferation evaluated by Ki-67 staining in cells with transfection for 72 hr or treatment with or without 20 mM chloroquine for 48 hr as indicated (n = 3).
(F) LDHB, LDHA, LC3-I, and LC3-II protein expression in cells treated overnight with or without leupeptin (150 mM) (n = 13). Autophagic flux was calculated as the
difference in LC3-II expression between conditions with and without leupeptin.
(G) Optineurin protein expression in cells transfected with siCTR or siLDHB-1 (n = 8).
(H) Numbers of cells 72 hr after transfection with siCTR or siLDHA (n = 6).
(I) Western blot quantification of LDHA and LC3-II in cells transfected as indicated and treated overnight with or without leupeptin (150 mM) (n = 4).
(J) Optineurin and LDHA protein expression (n = 4).
All data represent means ± SEM. *p < 0.05, **p < 0.01, ***p < 0.005; ns, not significant, by one-way ANOVA and Holm-Sidak’s multiple comparisons test (A and B),
two-tailed unpaired Student’s t test (C–E and H), Kruskal-Wallis and Dunn’s multiple comparisons test (F middle, I), or Mann-Whitney test (F right, G, and J).
See also Figure S2.effectively restored the number of SiHa cells transfected with an
siRNA targeting the 50-untranslated sequence of LDHB mRNA,
neither hLDHBD163-331 nor hLDHBD1-162 restored cell num-
ber (Figures 4A, S4A, and S4B). LDHB overexpression enhanced
siCTR cell number. In addition, theMCT1 inhibitor a-cyano-4-hy-
droxycinnamate (CHC), known to inhibit lactate uptake in SiHa
cells (Sonveaux et al., 2008), decreased cell number with no422 Cancer Cell 30, 418–431, September 12, 2016additional effect of siLDHB (Figure 4B). We therefore hypothe-
sized that the enzymatic activity of LDHB promotes lysosome
activity.
Upon glucose starvation, a condition stimulating autophagy
and increasing lysosomal proteolysis in SiHa cells (Figure S4C),
siLDHB decreased SiHa cell number (Figure 4C). Conversely,








Figure 3. LDHB Controls Autophagic Vesicle Maturation
(A) Representative immunoblots of subcellular fractions of SiHa cells (n = 3). Rab4 and cathepsin B are used asmarkers enriched in the endosomal and lysosomal
fractions, respectively.
(B) Representative electron micrographs of SiHa cells transfected as indicated (scale bar, 2 mm).
(legend continued on next page)
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in glucose-starved (Figure 4D) and in glucose-replenished cells
(Figure 4E). Lactate activated intracellular proteolysis in a
LDHB-dependent manner (Figure 4E), indicating that lactate
oxidation to pyruvate supports autophagy in oxidative cancer
cells. Accordingly, lactate triggered autolysosome formation
(Figure 4F), whereas CHC caused LC3-II protein accumulation
with no additive effect on siLDHB (Figure 4G).
To fully understand the molecular determinants responsible
for the control of autophagy by LDHB, we aimed to metaboli-
cally restore autophagy in LDHB-depleted SiHa cells. LDHB re-
action substrate lactate and product pyruvate did not restore
intracellular proteolysis (Figures 4E and 4H), but LDHB-
depleted cells had switched to a glycolytic metabolism (Figures
S4D and S4E), which, similar to MCT1 inhibition (Sonveaux
et al., 2008), can oppose lactate and pyruvate uptake. How-
ever, neither cell-permeable methyl-lactate nor methyl-pyru-
vate restored cell number (Figure S4F) or acidic vesicle
compartment size (Figure S4G), indicating that pyruvate down-
stream of LDHB does not promote autophagy. We therefore
focused on the conversion of NAD+ to NADH + H+ associated
with the oxidation of lactate by LDHB. While lactate induced
MCT1-dependent lysosome acidification in the presence of
LDHB (Figure 4I), siLDHB decreased the NADH/NAD+ ratio
(Figure 4J), which was associated with lysosome alkalinization
(Figures 4K, S4H, and S4I) but unchanged cytosolic pH
(Figure 4L). Thus, the LDHB reaction promotes lysosomal
acidification.
LDHB Promotes V-ATPase-Dependent Lysosomal
Acidification
V-ATPase is themajor contributor to lysosome acidification, with
two protons translocated for each ATP hydrolyzed (Beyenbach
and Wieczorek, 2006). Having found by proximity ligation assay
that LDHB is in close proximity to V-ATPase (Figure 5A), we used
co-immunoprecipitation and identified a physical interaction be-
tween LDHB and V-ATPase (Figure 5B). The V-ATPase inhibitor
bafilomycin A1 prevented the lysosomal acidification induced by
LDHB overexpression (Figures 5C and S5A), indicating that
LDHB promotes V-ATPase-dependent lysosomal acidification.
Main active proteases in SiHa cells are cysteine cathepsins B
(Figure S5B), the acid-dependent cleavage/activation of which
was also repressed by siLDHB (Figure 5D). This observation ex-(C) Acidic vesicle content measured using acridine orange staining in SiHa cells tr
(top graph, n = 4; bottom graph, n = 3).
(D) Representative images of LAMP1 immunostaining and quantification of lysos
(E) Quantification of lysosome distance to nucleus of images obtained in (D) (n =
(F) Evaluation of lysosome-autophagosome fusion in SiHa cells transfected as i
efficient calculation. Closed and open arrows show mature and immature autoph
(G) The abundance of autophagosomes and autolysosomes was measured with a
20 mM chloroquine for 48 hr as indicated (scale bar, 10 mm; n = 4).
(H) Representative images of LC3 immunostaining and quantification of LC3-po
roquine for 48 hr as indicated (scale bar, 10 mm; n = 3).
(I) Representative images and quantification of intracellular proteolysis by DQ-BS
(scale bar, 20 mm; n = 3).
(J) Autophagosomes and autolysosomes abundance measured with an LC3-GF
(K) Intracellular proteolysis measured with DQ-BSA in SiHa cells 48 hr after trans
All data representmeans ± SEM. *p < 0.05, **p < 0.01, ***p < 0.005; ns, not significa
two-tailed unpaired Student’s t test (D–F), or one-way ANOVA with Holm-Sidak’
See also Figure S3.
424 Cancer Cell 30, 418–431, September 12, 2016plains why lactate promotes and siLDHB decreases intracellular
proteolysis.
Interestingly, silencing LDHB decreased the number of all the
human cancer cell lines that we tested (Figure 1G), including
WiDr human colon cancer cells, which are aerobically glycolytic
(Warburg effect) (Sonveaux et al., 2008). Therefore, using an
isogenic series of cancer cells with different previously charac-
terized metabolic activities (Porporato et al., 2014), we finally
aimed to test whether LDHB also controls lysosomal activity in
glycolytic cancer cells that do not metabolically depend on
lactate oxidation for ATP production (Sonveaux et al., 2008).
siLDHB decreased the number of mitochondria-deficient
SiHa-r0 cells (Figures 5E and S5C) and induced acidic vesicle
accumulation (Figure 5F). In addition, siLDHA also decreased
the number of glycolytic SiHa-r0 cells with no additive effect of
chloroquine (Figures 5G and S5C), but not the number of wild-
type oxidative SiHa cells (Figure 2H). These results indicate
that glycolytic cancer cells use lactate-pyruvate cycling to main-
tain high lysosomal activity, whereas oxidative cancer cells use
extracellular lactate delivered by the glycolytic tumor compart-
ment to support autophagy (Figure 5H).
Finally, we confirmed the therapeutic potential of targeting
LDHB in cancer by comparing the antitumor efficacy of chloro-
quine and TET-on shLDHB-1 and shLDHB-3 on established
HCT116 tumors in mice, thus using the samemodel as in Figures
S1A and S1B but with two other shRNAs. Chloroquine and/or
doxycycline were administered 13 days after tumor implantation
once tumors reached 5 mm in diameter. Silencing LDHB with
shLDHB-1 or shLDHB-3 was more potent to retard HCT116 tu-
mor growth than chloroquine delivered at a dose of 25 mg/kg
every 3 days, and chloroquine did not significantly enhance the
effects of shLDHB-1 and shLDHB-3 (Figure 5I). Analysis of tumor
biopsies at the end of the treatments confirmed that the two
shRNAs inhibited autophagy in vivo, as they reduced the level
of ATG12 (Figures 5J and 5K), which is involved in autophago-
some formation (Geng and Klionsky, 2008) and is decreased
when autophagy is blocked (Ciccia et al., 2014; Aravindan
et al., 2015). Conversely, tumors expressing shLDHB signifi-
cantly accumulated LC3-II (Figure 5L), with an increased number
of LC3 foci in cancer cells (Figure 5M), and accumulated opti-
neurin (Figure S5G), indicating a blockage in the degradation
process. These differences were not seen when autophagyansfected as indicated and treated with or without 20 mM chloroquine for 48 hr
ome density in SiHa cells transfected as indicated (scale bar, 20 mm; n = 3).
3).
ndicated using LAMP1 and LC3 immunostaining and Pearson correlation co-
agosomes, respectively (scale bar, 20 mm; n = 3).
n LC3-GFP-mRFP reporter in SiHa cells transfected or treated with or without
sitive vesicles in SiHa cells transfected or treated with or without 20 mM chlo-
A dequenching in SiHa cells treated with or without 20 mM chloroquine for 48 hr
P-mRFP reporter in SiHa cells 48 hr after transfection (n = 4).
fection (n = 3).
nt, Kruskal-Wallis with Dunn’s test (C, G, I, and J), Mann-Whitney test (C and K),








Figure 4. Lactate Promotes LDHB-Dependent Autophagy in Oxidative Cancer Cells
(A) Numbers of SiHa cells transfected with indicated siRNA without or with ectopic expression of LDHB, hLDHBD163-331, or hLDHBD1-162 (n = 5–7).
(B) Numbers of SiHa cells transfected with indicated siRNA and then treated with or without 10 mM CHC for 48 hr (n = 6).
(C) Numbers of SiHa cells transfected as indicated after glucose and serum starvation for 6 hr (n = 6).
(D and E) Representative images and quantification of intracellular proteolysis by DQ-BSA in SiHa cells grown without (D) or with (E) glucose and with or without
treatment with 10 mM lactate (scale bars, 20 mm; 48 hr treatment, n = 4 per group).
(F) Abundance of autophagosomes and of autolysosomesmeasured with LC3-GFP-mRFP in SiHa cells treated with or without 10mM lactate for 48 hr (scale bar,
20 mm; n = 4).
(G) LDHB, LC3-I, and LC3-II protein abundance in SiHa cells treated with or without 10 mM CHC for 48 hr (n = 4).
(legend continued on next page)
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was inhibited by chloroquine treatment in mice (Figures 5J–5M
and S5D–S5G). Together, our results demonstrate that LDHB
is a credible target for autophagy inhibition in cancer.
DISCUSSION
Our study positions LDHB as a key contributor to lysosomal ac-
tivity and autophagy in cancer. Lysosomal acidification depends
on LDHB activity both in oxidative cancer cells and in glycolytic
cancer cells, and silencing LDHB selectively inhibits the prolifer-
ation of cancer compared with normal differentiated cells, thus
unraveling LDHB as a promising anticancer target. For therapy,
LDHB inhibitors would offer a targeted and more selective alter-
native to the lysosomotropic agent chloroquine and its deriva-
tives, which act as weak bases. Indeed, chloroquine exerts
side effects that are independent of autophagy inhibition (May-
cotte et al., 2012; Maes et al., 2014), and its activity decreases
with tumor acidity (Pellegrini et al., 2014).
LDHB is a key component of the oxidative pathway of lactate
that controls metabolic cooperativeness between glycolytic and
oxidative cancer cells (Sonveaux et al., 2008; Leite et al., 2011).
In the metabolic cooperation where oxidative cancer cells use
lactate preferentially to glucose, getting access to glucose is a
clear metabolic advantage for glycolytic cancer cells. In turn,
we report that oxidative cancer cells get a high autophagic flux
as a metabolic reward. Mutual benefit resulting from lactate ex-
changes between different types of cancer cells substantiates
the hypothesis of a metabolic symbiosis (Sonveaux et al.,
2008). According to the extended version of the model (Fig-
ure 5H), lactate produced glycolytically diffuses to the oxidative
cancer cell compartment, enters into oxidative cancer cells pref-
erentially via MCT1, and lactate and NAD+ are converted to py-
ruvate, NADH, and H+ by LDHB. While pyruvate and NADH
fuel oxidative mitochondrial metabolism (Sonveaux et al., 2008;
Van Hee et al., 2015), protons promote V-ATPase-dependent
lysosomal acidification and autophagy, which is facilitated by a
close interaction between LDHB and V-ATPase at the lysosomal
surface. In oxygenated cancer cells that rapidly oxidize lactate, a
high autophagic flux would primarily facilitate the recycling of
damaged cellular components (Rabinowitz and White, 2010).
High oxidative activities are indeed associated with elevated
oxidative stress, and a major function of autophagy is to recycle
oxidized proteins and organelles (Navarro-Yepes et al., 2014).
In oxidative cancer cells, LDHB couples lactate oxidation with
autophagy not only when extracellular lactate is provided at a
clinically relevant concentration (Walenta and Mueller-Klieser,
2004) (lactate-induced autophagy) but also under basal condi-
tions when low levels of lactate are available (basal autophagy).
Comparatively, glycolytic cancer cells generate high amounts of
intracellular lactate from pyruvate via the LDHA reaction. Lactate
can either be exported, primarily via MCT4 to support metabolic(H) Intracellular proteolysis in SiHa cells treated with or without 10 mM pyruvate
(I) Lysosomal pH measured with FITC-dextran in SiHa cells treated with or witho
(J) NADH/NAD+ ratio measured enzymatically (n = 3).
(K) Lysosomal pH (n = 4).
(L) Intracellular pH measured with SNARF-1-AM (n = 4).
All data represent means ± SEM. *p < 0.05, **p < 0.01, ***p < 0.005; ns, not signifi
and I), two-tailed unpaired Student’s t test (C and J–L), Mann-Whitney test (D), or K
426 Cancer Cell 30, 418–431, September 12, 2016symbiosis, or it can be oxidized back to pyruvate by LDHB (Fig-
ure 5H). At first glance, this could be seen as a futile cycle, but it is
not. LDHB is indeed needed to sustain autophagy and glycolytic
cancer cell survival. In the process, similar to what happens in
oxidative cancer cells, lactate and NAD+ are converted to pyru-
vate, NADH, and H+ by LDHB. Protons generated by LDHB
promote V-ATPase-dependent lysosomal acidification and
autophagy which, in these cells that often reside in metabolically
restricted microenvironments, would constitute an additional
source of energetic and biosynthetic precursors (Rabinowitz
and White, 2010). Transferring protons to lysosomes would
also contribute to the pH homeostasis of the cytosol (Spugnini
et al., 2014).
Blocking basal autophagy can kill cancer cells (Avalos et al.,
2014), and we report that silencing LDHB inhibits basal auto-
phagy and cancer cell proliferation and induces apoptotic cell
death. Three characteristics of the response are remarkable.
First, silencing LDHB is as effective as chloroquine in inhibiting
autophagy. Second, silencing LDHB generally impairs the
expansion of human cancer cell lines. Of note, we found that
MCF7 cells that are relatively non-dependent on autophagy
(Yang et al., 2011; Mancias et al., 2014; Maycotte et al., 2014)
are the least sensitive; and autophagy-dependent, Ras-mutated
HCT116 cells (Guo et al., 2011) are the most sensitive to LDHB
silencing. Third, silencing LDHB shows selectivity for cancer
versus normal differentiated cells. Thus, compared with chloro-
quine and its derivatives that are currently undergoing clinical tri-
als but act in a non-targeted and non-specific manner, targeting
LDHB could offer a unique opportunity to inhibit a precise target
controlling lysosomal activity and autophagy preferentially in
cancer cells. Compared with other components of lactate meta-
bolism, we propose LDHB as a preferred target to simulta-
neously inhibit autophagy in glycolytic and oxidative cancer
cells. In comparison, inhibiting LDHA or MCT4 would decrease
the autophagic flux only in glycolytic cancer cells, and targeting
MCT1 would block autophagy only in oxidative cancer cells. In
support of this, LDHB is an independent prognostic marker of
overall survival in uterine cancer patients and promotes the pro-
gression of several different types of tumors (De Haas et al.,
2008; Yoo et al., 2009; Hussien and Brooks, 2011; Isozaki
et al., 2012; McCleland et al., 2012; Beronja et al., 2013; Denni-
son et al., 2013; Koshiyama et al., 2013; McCleland et al., 2013).
Previous studies further indicated that complete hereditary defi-
ciency of LDHB has no symptomatic consequences in humans
(Okumura et al., 1999; Sudo et al., 1999), thus supporting the
future clinical development of pharmacological inhibitors of
LDHB.
Similarly to other inhibitors of autophagy that display most of
their therapeutic activity in combination with other anticancer
therapies (Chen and Karantza-Wadsworth, 2009; Chen et al.,
2010; Amaravadi et al., 2011), silencing LDHB had only limitedfor 48 hr (scale bar, 20 mm; n = 3).
ut 10 mM sodium lactate with or without 10 mM CHC for 48 hr (n = 4).
cant, by one-way ANOVA with Holm-Sidak’s multiple comparisons test (A, B,








(legend on next page)
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effects at the beginning of tumor progression, but stronger ef-
fects were seen when silencing was induced at a later time point.
Resistance is unlikely to arise from LDHB re-expression or an
expressional compensation by LDHA, but could potentially result
from metabolic adaptations, in particular switching to a more
glycolytic metabolism in an aerobic environment in order to
compensate for autophagy inhibition (White, 2012).
Conclusively, we believe that identifying that lactate and LDHB
control lysosomal activity and autophagy preferentially in cancer
cells lays the ground for promising anticancer applications.
EXPERIMENTAL PROCEDURES
Patient Database Analysis
The SurvExpress gene expression database (Aguirre-Gamboa et al., 2013)
was used for the analysis of overall survival in Uterine Corpus Endometrioid
Carcinoma TCGA (332 samples). Patients were classified into two risk groups
according to gene expression and censored for overall survival without
stratification.
In Vivo Experiments
All in vivo experiments were performed with the approval of UCL Comité
d’Ethique pour l’Expérimentation Animale (approval ID: TUMETABO) accord-
ing to national and European animal care regulations. Tumor generation with
SiHa and with HCT116 cells expressing shCTR or shLDHB-1 and growth
rate determination were conducted as previously described (De Saedeleer
et al., 2012). A detailed description of the Experimental Procedures is provided
in Supplemental Experimental Procedures.
Cells and Reagents
All cell lines were from ATCC, except SKOV3 human ovarian carcinoma cells
(Wintzell et al., 2012), T98G and U373 human glioblastoma cells (Bruyere
et al., 2011), and HUVECs (Sigma-Aldrich). Details on culture conditions are
provided in Supplemental Experimental Procedures. Unless stated otherwise,
all chemicals were from Sigma-Aldrich. To avoid changes in extracellular pH,
lactate and pyruvate were used as sodium salts or methylated cell-permeable
forms. For functional assays, all data were normalized for cell number or total
protein content.
Cell Number, Proliferation, and Apoptosis
Cell number and cell death were measured using trypan blue exclusion on a
NucleoCounter device (ChemoMetec). Apoptosis was assayed by measuringFigure 5. LDHB Promotes V-ATPase-Dependent Lysosomal Acidificati
(A) Representative images of a proximity ligation assay of SiHa cells transfected as
and F-actin is stained in green with phalloidin-FITC. The graph shows mean num
(B) Co-immunoprecipitation of LDHB with the V-ATPase A1 subunit in SiHa cells
(C) SiHa cells transfected with an empty vector or with a plasmid encoding full-len
or without 100 nM bafilomycin A1 (n = 4).
(D) Mature and immature lysosomal cysteine cathepsins B detected by immunob
(E–G) Cell number (n = 3) (E), cell content in acidic vesicles measured using acridi
20 mM chloroquine for 48 hr (n = 6) (G) of SiHa-r0 cells.
(H) Model describing the contribution of LDHB to lysosomal activity in a metabolic
cells.
(I) Mice were implanted with HCT116 cancer cells carrying shCTR, shLDHB-1,
water 13 days after tumor inoculation. Where indicated, 25 mg/kg chloroquine
bearing an shCTR and a shLDHB tumor, and experiments were run simultaneo
initiation (n = 6–14 mice per group).
(J and K) Western blot analysis of LDHB expression and immunohistochemical d
shLDHB-3 and matched shCTR (K, n = 6) tumors at the end of the experiment sh
(L and M) Western blot (L) and immunohistochemistry (M) analysis of LC3-I and LC
shown in (I) (n = 8; scale bar, 20 mm).
All data represent means ± SEM. *p < 0.05, **p < 0.01, ***p < 0.005; ns, not signifi
test (F), one-way ANOVA with Holm-Sidak’s multiple comparisons test (C, G, J,
See also Figure S5.
428 Cancer Cell 30, 418–431, September 12, 2016caspase-3 cleavage usingwestern blotting. Cell proliferation was evaluated by
immunocytochemistry using a mouse monoclonal antibody against Ki-67
(556003, BD Biosciences), and expressed as the percentage of Ki-67-positive
cells in the total nuclei count on thresholded images using ImageJ software
1.46r.
RNAi and Cell Transfection
shRNAs were delivered with lentiviruses, and siRNAs and plasmids using
transfection. Details are provided in Supplemental Experimental Procedures.
Co-immunoprecipitation and Western Blotting
Co-immunoprecipitation was performed using Dynabeads protein G (Invitro-
gen) according to the manufacturer’s protocol. Immunoblotting was per-
formed as previously described (Feron et al., 1996). Details are provided in
Supplemental Experimental Procedures.
Immunochemistry and Proximity Ligation Assay
Immunohistochemistry and immunocytofluorescence labeling were per-
formed as previously described (Sonveaux et al., 2008). In situ protein-protein
interactions were detected using the proximity ligation assay (Duolink kit) from
Olink Bioscience according to themanufacturer’s instructions. Details are pro-
vided in Supplemental Experimental Procedures.
Cell Fractionation
Cells fractionation was performed according to Schroter et al. (1999). The pro-
cedures are detailed in Supplemental Experimental Procedures.
Electron Microscopy
Transmission electron microscopy was performed using a previously
described protocol (Piret et al., 2012).
Endosome, Lysosome, and Autophagic Assays
Endocytic trafficking was measured using a previously described transferrin
recycling assay (Magadan et al., 2006). Intracellular proteolysis was
quantified based on the intracellular degradation of fluorogenic substrate
DQ green BSA (Invitrogen). Acidic vesicles were determined using acridine
orange (Sigma) fluorescence measurements, lysosomal pH after overnight
endocytosis of 0.5 mg/mL of pH sensitive FITC-dextran (Sigma) by intact
cells (Vidal-Donet et al., 2013), and autophagosome maturation with an
mRFP-GFP-LC3-encoding construct (Plasmid 21074: ptfLC3; Addgene)
used according to Kimura et al. (2007). Cytosolic pH was measured
using SNARF-1-AM. Details are provided in Supplemental Experimental
Procedures.on in Oxidative and Glycolytic Cancer Cells
indicated. LDHB-V-ATPase A1 protein-protein interactions appear as red dots
ber of interactions per cell (scale bar, 20 mm; n = 3).
(representative of n = 3).
gth LDHB. Lysosomal pH was assayed 48 hr later in cells treated overnight with
lotting in SiHa cells transfected as indicated (n = 5).
ne orange staining (n = 3) (F), and cell number after a treatment with or without
symbiosis based on lactate exchange between glycolytic and oxidative cancer
or shLDHB-3, and 2 mg/mL doxycycline were administered via the drinking
was administered by intraperitoneal injection every 3 days. Each mouse was
usly. The graph depicts tumor growth normalized to tumor size at treatment
etection of ATG12 expression in shLDHB-1 and matched shCTR (J, n = 8) or
own in (I).
3-II in the shLDHB-1 and matched shCTR tumors at the end of the experiment
cant, by two-tailed unpaired Student’s t test (A, D, E, L, and M), Mann-Whitney
and K).
Metabolic Assays
For metabolic assays, an equal number of cells were plated in 6-well plates in
fresh medium. Seventy-two hours later, glucose and lactate concentrations
were measured in deproteinized cell supernatants using specific enzymatic
assays on a CMA600 Microdialysis Analyzer (CMA Microdialysis). Data were
normalized to final cell numbers.LDHB Activity
LDHB activity was measured in intact cells using the NADH/NAD+ ratio that
was quantified in clear cell lysates using the NAD/NADH Quantitation Kit
from Source Bioscience according to manufacturer’s instructions. In cell ly-
sates, measurements of LDHB activity were performed using the lactate dehy-
drogenase B activity assay kit (Abcam) following manufacturer’s instructions.Statistics
All data were normalized to control and presented as means ± SEM; n corre-
sponds to the number of independent experiments. In some figures, the SEM
is smaller than the symbols. Two-tailed unpaired Student’s t test, Mann-
Whitney test, Wilcoxon signed rank test, one-way ANOVA followed by Holm-
Sidak’s multiple comparison test, Kruskal-Wallis followed by Dunn’s multiple
comparison test, and two-way ANOVA were used where appropriate. A log
rank test was used to compare survival curves. p < 0.05 was considered to
be statistically significant. Methods and any associated references are avail-
able in Supplemental Information.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and five figures and can be found with this article online at http://dx.doi.org/
10.1016/j.ccell.2016.08.005.AUTHOR CONTRIBUTIONS
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